| | | Note: This ASCO poster by Moffitt is in addition to Agarwala's (St. Lukes) Poster Highlights Session. So PV-10 will have two exposures, both by "name brand" organizations.
********************************************************************************
Provectus Biopharmaceuticals' PV-10 Data to Feature in Poster Presentation by Moffitt Cancer Center at the American Society of Clinical Oncology (ASCO) Annual Meeting
Wednesday April 2, 2014
McCormick Place in Chicago, IL, May 30-June 3, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), announced today that data on its investigational drug PV-10 will be featured in a presentation by investigators from Moffitt Cancer Center in a Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL, May 30-June 3, 2014. The time and date of the presentation are expected to become available on the ASCO website, http://am.asco.org, on April 21, 2014.
The poster, based upon abstract #9028, is entitled "Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions," and is authored by Amod Sarnaik, MD and colleagues of Moffitt.
Craig Dees, PhD, CEO of Provectus said, "We value our relationship with Moffitt greatly, and we are excited by the assessment Dr. Sarnaik has made on clinical and immunologic activity of intralesional PV-10."
Provectus has recently submitted an application to the FDA for breakthrough therapy designation for PV-10 based on the results from its Phase 2 clinical study of melanoma and is researching its efficacy for other indications.
The complete press release is available at www.pvct.com/pressrelease.html?article=20140402 on the Provectus website. |
|
